PEPGEN INC. Deferred Offering Costs
PEPGEN INC. (PEPG) had Deferred Offering Costs of $400.00 thousand as of 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Balance Sheet
us-gaap:DeferredOfferingCosts · last filed 2024-08-08
- 2024-06-30: Deferred Offering Costs $400.00K.
- 2024-03-31: Deferred Offering Costs $300.00K.
- 2023-12-31: Deferred Offering Costs $4.10M.
- 2023-09-30: Deferred Offering Costs $4.10M.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2024-06-30 | $400.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $300.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $4.10M 10-K/A · filed 2024-03-29 | |
| 2023-09-30 | $4.10M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $4.10M 10-Q · filed 2023-08-08 | |
| 2022-12-31 | $4.10M 10-K · filed 2023-03-23 | |
| 2022-09-30 | $4.10M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $4.10M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $4.10M 10-Q · filed 2023-05-11 | $2.20M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |